Home » Stocks » ANIP

ANI Pharmaceuticals, Inc. (ANIP)

Stock Price: $34.19 USD -0.05 (-0.15%)
Updated Jun 16, 2021 4:00 PM EDT - Market closed
Market Cap 436.21M
Revenue (ttm) 213.22M
Net Income (ttm) -15.45M
Shares Out 12.02M
EPS (ttm) -1.29
PE Ratio n/a
Forward PE 9.10
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $34.19
Previous Close $34.24
Change ($) -0.05
Change (%) -0.15%
Day's Open 34.14
Day's Range 33.47 - 34.45
Day's Volume 43,416
52-Week Range 23.55 - 40.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Offic...

1 day ago - Business Wire

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI“ or the “Company“) (Nasdaq: ANIP) today announced log-in details for its 2021 Virtual Annual Meeting of Stockholders to be held on June ...

2 weeks ago - Business Wire

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Offic...

2 weeks ago - Business Wire

ANIP, BHVN, FVRR, KBAL, and PLNT have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2021

Other stocks mentioned: BHVN, FVRR, KBAL, PLNT
3 weeks ago - Zacks Investment Research

ANI (ANIP) delivered earnings and revenue surprises of 42.47% and 13.59%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three months ended March 31, 2021. F...

1 month ago - Business Wire

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2021 financial results on Friday, May ...

1 month ago - Business Wire

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI”) (NASDAQ:ANIP) today announced that it has acquired the new drug applications (“NDAs”) for OXISTAT® Lotion, VEREGEN® Ointment, and Pand...

2 months ago - Business Wire

ANI Pharmaceuticals (ANIP) has moved higher as of late, but there could definitely be trouble on the horizon for this company

2 months ago - Zacks Investment Research

ANI (ANIP) delivered earnings and revenue surprises of -20.00% and 3.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and 12 months ended December 3...

3 months ago - Business Wire

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held...

3 months ago - Business Wire

ANI Pharmaceuticals (NASDAQ:ANIP) announces its next round of earnings this Tuesday, March 09. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement.

3 months ago - Benzinga

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI“ or the “Company“) (Nasdaq: ANIP) today announced that ANI's Board of Directors granted non-qualified inducement stock options to purcha...

3 months ago - Business Wire

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the addition of three key pharmaceutical executives: Christopher K. Mutz as Chief Comm...

3 months ago - Business Wire

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2020 financial results ...

3 months ago - Business Wire

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prazosin HCl Capsules USP, 1mg and 2mg, following the U.S. Food and Drug...

4 months ago - Business Wire

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval and the launch of Aminocaproic Acid T...

5 months ago - Business Wire

Let's see if ANI Pharmaceuticals (ANIP) stock is a good choice for value-oriented investors right now from multiple angles.

6 months ago - Zacks Investment Research

ANI Pharmaceuticals, Inc.'s (ANIP) CEO Nikhil Lalwani on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

According to the GuruFocus All-in-One Screener as of Nov. 5, the following medical technology stocks are popular among gurus.

Other stocks mentioned: SRGA, VNDA, PETS, SRDX
7 months ago - GuruFocus

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and nine months ended Septembe...

7 months ago - Business Wire

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2020 financial results on Thursday, No...

7 months ago - Business Wire

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc.

9 months ago - Business Wire

ANI Pharmaceuticals, Inc. (ANIP) CEO Patrick Walsh on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

ANI (ANIP) delivered earnings and revenue surprises of -2.82% and 6.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc.

10 months ago - Business Wire

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc.

10 months ago - Business Wire

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc.

10 months ago - Business Wire

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc.

10 months ago - Business Wire

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

BAUDETTE, Minn., July 6, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the acquisition of Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg from a private co...

11 months ago - PRNewsWire

ANI Pharmaceuticals: Significantly Undervalued

11 months ago - Seeking Alpha

Here's why a new initiative by the FDA to reduce drug prices is great for patients but should raise the alarm among pharmaceutical investors.

Other stocks mentioned: LCI, MYL, PFE, TARO, TEVA
1 year ago - The Motley Fool

ANI Pharmaceuticals, Inc. (ANIP) CEO Arthur Przybyl on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

ANI (ANIP) delivered earnings and revenue surprises of 16.85% and 0.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

1 year ago - Zacks Investment Research

A small-cap pharmaceuticals company may hold the solution to a nearly 100,000% drug price hike.

1 year ago - The Motley Fool

ANI Pharmaceuticals, Inc. (ANIP) CEO Arthur Przybyl on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

ANI (ANIP) delivered earnings and revenue surprises of -8.47% and -6.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Why ANI Pharmaceuticals Considers Corticotropin Gel Its Blockbuster Drug

1 year ago - Seeking Alpha

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

Other stocks mentioned: IMMU, MRTX, PTCT
1 year ago - Zacks Investment Research

ANI Pharmaceuticals could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

1 year ago - Zacks Investment Research

ANI (ANIP) delivered earnings and revenue surprises of -16.89% and -10.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: AIZ, AVA, EXPI, OPRA
1 year ago - Zacks Investment Research

About ANIP

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, ... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2001
CEO
Patrick Walsh
Employees
369
Stock Exchange
NASDAQ
Ticker Symbol
ANIP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ANIP stock is "Buy." The 12-month stock price forecast is 45.00, which is an increase of 31.62% from the latest price.

Price Target
$45.00
(31.62% upside)
Analyst Consensus: Buy